Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...
Mol Cancer Ther (2025) 24 (10_Supplement): B004.
Abstract. Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. At the time of diagnosis, it is ...
Cancer Epidemiol Biomarkers Prev (2009) 18 (6): 1740–1745. The U.S. active-duty military population may differ from the U.S. general population in its exposure to cancer risk factors and access to ...
You do not currently have access to this content.
*Corresponding Author: Sandra J. Casak, Office of Oncology Drugs, CDER, U.S. Food and Drug Administration, WO22 Room 2200, 10903 New Hampshire Avenue, Silver Spring ...
1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China.
1Yonsei University, College of Medicine, Seoul, Republic of Korea.
1School of Medicine, University of California San Diego, La Jolla, California. *Corresponding Author: James T. Robinson, School of Medicine, University of California ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results